GW Pharmaceuticals Plc

GW Pharmaceuticals Plc

GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
Biotechnology
Company Details
Sector
Healthcare
Industry
Drug Manufacturers - Major
Full time employees
776
Country
United Kingdom

GW Pharmaceuticals Plc News

24 May

Comparing GW Pharmaceuticals’ Returns to Peers

Comparing GW Pharmaceuticals’ Returns to PeersGW PharmaceuticalsGW Pharmaceuticals (GWHP) is primarily into the development of cannabis-derived prescription medicines. Liquid cannabidiol (or CBD) is the...

24 May

GW Pharmaceuticals (GWPH) Stock Could Run Much Higher Over Time

GW Pharmaceuticals (GWPH) has recently bounced after a solid earnings report. It also announced its phase-3 trial concerning its Epidiolex oral medicine, received positive results.The combination of the...

23 May

My Top 3 Companies Paving The Way For Medicinal Cannabis Research

The green rush is nothing new to investors that have been following developments over the last few years. As legalization across the nation continues to grow and with mounting pressure on the federal government...

20 May

GW Pharmaceuticals PLC (GWPH) Is Up 1.6% in One Week: What You Should Know

Does GW Pharmaceuticals PLC (GWPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

20 May

3 Gene Therapy Stocks For A Biotech Portfolio

Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential...

16 May

The Smartest People on Wall Street Are Buying These 3 Stocks -- Should You Follow?

Why are billionaire investors betting on stocks like Disney and GW Pharmaceuticals?

16 May

If You Had Bought GW Pharmaceuticals (NASDAQ:GWPH) Stock Five Years Ago, You Could Pocket A 171% Gain Today

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...

13 May

3 ‘Strong Buy’ Cannabis Stocks Set For Rapid Growth

The cannabis market has the potential to be extremely lucrative for investors. For example Quebec-based cannabis grower Hexo Corp (HEXO) is now up 107% year-to-date. But you have to know which stocks to...

10 May

The Zacks Analyst Blog Highlights: GW Pharmaceuticals, Scotts Miracle-Gro, Ambev, International Game Techno

The Zacks Analyst Blog Highlights: GW Pharmaceuticals, Scotts Miracle-Gro, Ambev, International Game Technology and Ubisoft Entertainment

09 May

GW Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May

LONDON, May 09, 2019 -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science,.

Load more

About GW Pharmaceuticals Plc

GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.

GW has developed an oral formulation of purified cannabidiol (CBD), approved as Epidiolex® in the U.S. by the U.S. Food and Drug Administration (FDA) for seizures associated with Lennox-Gastaut syndrome or Dravet Syndrome, two rare and severe early-onset, drug-resistant epilepsy syndromes. This is the first cannabis plant-derived medicine ever approved by the FDA and it has been rescheduled by the U.S. DEA to a schedule V. The medicine was launched in the US as a prescription medicine by our US operating subsidiary, Greenwich Biosciences Inc., on November 1, 2018. GW has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) with an expected decision date in early 2019.

GW successfully developed the world’s first prescription medicine derived from the cannabis plant, called Sativex® (delta-9-tetrahydrocannibinol and cannabidiol in the EU; nabiximols in the US), which is now approved in over 25 countries outside of the US for the treatment of spasticity due to multiple sclerosis. GW continues to research and develop Sativex.

The company has a deep pipeline of additional clinical stage cannabinoid product candidates under development for both orphan and non-orphan indications with a particular focus on neurological conditions.

GW Pharmaceuticals was founded in 1998 and is listed on the NASDAQ Global Market (GWPH). The company has operations in both the US and the UK.

Team

Dr. Geoffrey Guy
Chairman and Founder
Justin Gover
Chief Executive Officer and Executive Director
Cabot Brown
Non-Executive Director
Thomas Lynch
Non-Executive Director
James Noble
Non-Executive Director (Deputy Chairman)
Catherine Mackey, Ph...
Non-Executive Director
Alicia Secor
Non-Executive Director
Lord William Waldegr...
Non-Executive Director
$ 183.62
-0.01%
Open:
185.19
High:
187.69
Low:
181.50
Share volume:
311.868 K
Total value:
49.658 M
Market cap:
5.641 B
Symbol:
GWPH